Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02233582
Other study ID # Ibuprofen and Altitude
Secondary ID IRB#14-14110
Status Completed
Phase Phase 1
First received
Last updated
Start date September 2014
Est. completion date June 2017

Study information

Verified date April 2021
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Ibuprofen is often taken by travelers to high altitude to treat the symptoms of acute mountain sickness such as headache and malaise. However, the blunting of inflammation by ibuprofen may slow the process of acclimatization to altitude, which relies on mediators of inflammation for adjustments in breathing. The study randomizes healthy subjects to receive ibuprofen or placebo and then ascend to altitude (12,500 feet). Blood cytokines and non-invasive measurements of blood and tissue oxygen levels will be made for 48 hours at altitude. The hypothesis being tested is that subjects receiving ibuprofen will have lower blood and tissue oxygen levels after 48 hours at altitude than will placebo subjects.


Description:

The study will begin with 2 days of studies in San Francisco (sea level baseline). Measurements will include non-invasive measurements of blood and tissue oxygen and venous blood draws for cytokine levels. The altitude part of the study involves ascent to the University of California's White Mountain Research Center Barcroft Laboratory, at 12,500 feet elevation. The subjects will remain at that altitude for at least 48 hours for measurements of oxygenation and blood cytokines.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date June 2017
Est. primary completion date October 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - healthy subjects The group of subjects in this experiment will be composed of healthy adult volunteers, over age 18 and under age 65, of any ethnic group, in good physical and mental health. We expect to enroll approximately 20 subjects. The ethnic groups represented will depend on the ethnicity of those who wish to be subjects, but no ethnic groups will be specifically sought after or rejected. Exclusion Criteria: Subjects will be specifically excluded according to the following criteria: 1. History of any clinically significant medical condition, particularly abnormal respiratory, cardiovascular, neurological, hematological, renal or hepatic function. A medical history and physical exam will be performed at the screening session for each subject. We will use this to determine whether the subjects are healthy and without any history of these conditions. No laboratory workup will be required 2. Regular smokers (more than 1 cigarette or cigar per day). 3. Currently active or recently treated systemic or serious local infection. 4. Recent regular use of prescription medications or regular physician care for any significant medical condition. 5. A history of high altitude pulmonary edema or high altitude cerebral edema. 6. Recent exposure to altitude (>8000 ft) in the last month or having slept at an altitude >6000 feet in the last month. 7. Inability to provide written informed consent or to be able to complete the experiment. 8. Pregnancy as determined by a urine pregnancy test if subjects believe they might be pregnant 9. Allergy to non-steroid anti-inflammatory drugs (NSAIDs) or subjects reporting history or symptoms of ulcers or other ibuprofen related contraindications discussed with the screening physician. 10. Heavy coffee drinkers or caffeine users will be advised that they may suffer rebound headache when restricted from caffeinated beverages on measurement days, and asked to carefully consider any continuing participation in the study after abstaining from caffeine during their first sea level measurements.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ibuprofen
We are simply testing if taking ibuprofen upon ascent to altitude is associated with a delayed acclimatization response to the high altitude hypoxia.
Sugar pill


Locations

Country Name City State
United States White Mountain Research Center Bishop California
United States UCSF Hypoxia Research Laboratory San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other cerebral oximetry non-invasive measurements of cerebral oxygenation with an FDA approved device once daily for 2 days at sea level, on arrival at altitude and daily for 2 days
Other acute mountain sickness inventory standard questionnaire concerning symptoms associated with acute mountain sickness once a day at both sea level (2 days) and altitude (2 days)
Primary blood cytokine levels venous blood sample, once a day on days 1 and 2 at sea level, on arrival at altitude and daily for 2 days
Primary cerebral blood flow optical/non-invasive measure of frontal cortex cerebral blood flow with an FDA-approved device once daily for 2 days at sea level, on arrival at altitude and once daily at altitude for 2 days
Secondary pulse oximetry finger pulse oximetry with an FDA approved pulse oximeter once a day for 2 days at sea level, on arrival at altitude and daily for 2 days
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06133530 - Human Milk Oligosaccharides (HMOs) and Gut Microbiota, Immune System in Antarctica N/A
Active, not recruiting NCT04604249 - Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World
Not yet recruiting NCT05063643 - Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude
Recruiting NCT05474287 - SJOV vs. HFNO for Hypoxia During Procedural Sedation at High Altitudes N/A
Completed NCT06392373 - High Altitude Muscle Recovery N/A
Completed NCT03851744 - High Altitude and Exogenous Carbohydrate Oxidation N/A
Completed NCT01830530 - HIGH Altitude CArdiovascular REsearch in the ANDES Phase 4
Completed NCT06164665 - Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude Phase 4
Recruiting NCT06393998 - CO2 Supplement for Treatment of Acute Mountain Sickness N/A
Not yet recruiting NCT06446427 - The Effect of Acute High Altitude Exposure on Rescuer Performance and Patient Care N/A
Completed NCT04915378 - Hypoxia-altitude Testing to Predict Altitude Related Adverse Health Effects in Chronic Obstructive Pulmonary Disease (COPD) Patients
Completed NCT04290481 - Oxygen Saturation and Perfusion Index ın Neonates at High Altitude
Completed NCT05798416 - Effect of Inhalation of Low Dose CO2 on Exercise Performance at High Altitude N/A
Completed NCT05715476 - The Effect of Different Altitude Levels on Spinal Anesthesia in Cesarean Section Surgery N/A
Recruiting NCT05115721 - Establishing the Reference Interval for Pulse Oxygen Saturation in Neonates at High Altitude
Recruiting NCT06152744 - Evaluation of Membrane Lung Function in High-altitude Regions
Recruiting NCT05304923 - Supraglottic Jet Oxygenation and Ventilation for Gastrointestinal Endoscopy at High-altitude N/A
Recruiting NCT04199650 - Definition of ARDS in Qinghai Province: Verification of Berlin Definition Plateau Criteria